OBJECTIVE: To report acute hematological toxicity (HT) in patients receiving post-operative bowel sparing intensity-modulated radiotherapy (IMRT) and cisplatin and its dosimetric predictors. METHODS: Clinical database of Phase III trial (NCT01279135), that randomized patients to post-operative conformal or intensity modulated radiation therapy, was searched to select patient strata that received bowel sparing IMRT (50 Gy/25#/5 wks) and concurrent cisplatin (40 mg m-2). Pelvic bone marrow (BM) was retrospectively delineated in two sets: whole bone (WB), and freehand (FH) inner cavity of bone. Dose volume histograms (DVH) of BM were obtained. Receiver operating characteristic (ROC) curve identified DVH thresholds that predicted for Grade≥ II HT with highest specificity. Univariate and multivariate analysis was performed. RESULTS: Overall 75 patients received concurrent cisplatin. Grades I-V HT was observed in 38.7%, 42.7%, 14.7%, 0%, and 0% patients, respectively. Grade ≥ II leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 26%, 40%, 26.5%, and 1.4% respectively. None of the HT resulted in treatment break. On univariate analysis, whole pelvis+ lumbar FH V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, and lower pelvis WB and FH V40 >20% correlated for Grade ≥ II leucopenia and neutropenia. None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis. CONCLUSION: The IMRT arm of NCT01279135 (PARCER study) that employed strict bowel constraints had unintentional but desirable BM sparing. None of the BM subvolume DVH parameters could be validated on multivariate analysis. ADVANCES IN KNOWLEDGE: The prospective study reports feasibility of bone marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cervical cancer. The present study reports low incidence of hematological and gastrointestinal toxicity during post-operative chemoradiation with IMRT. As both whole bone and freehand pelvis BM contours predicted for HT, hence an easier method of whole bone contouring should continue to be used till further validation of more specific BM subvolumes becomes available. The study results highlight the need for further research into dose volume constraints during post-operative IMRT.
OBJECTIVE: To report acute hematological toxicity (HT) in patients receiving post-operative bowel sparing intensity-modulated radiotherapy (IMRT) and cisplatin and its dosimetric predictors. METHODS: Clinical database of Phase III trial (NCT01279135), that randomized patients to post-operative conformal or intensity modulated radiation therapy, was searched to select patient strata that received bowel sparing IMRT (50 Gy/25#/5 wks) and concurrent cisplatin (40 mg m-2). Pelvic bone marrow (BM) was retrospectively delineated in two sets: whole bone (WB), and freehand (FH) inner cavity of bone. Dose volume histograms (DVH) of BM were obtained. Receiver operating characteristic (ROC) curve identified DVH thresholds that predicted for Grade≥ II HT with highest specificity. Univariate and multivariate analysis was performed. RESULTS: Overall 75 patients received concurrent cisplatin. Grades I-V HT was observed in 38.7%, 42.7%, 14.7%, 0%, and 0% patients, respectively. Grade ≥ II leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 26%, 40%, 26.5%, and 1.4% respectively. None of the HT resulted in treatment break. On univariate analysis, whole pelvis+ lumbar FH V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, and lower pelvis WB and FH V40 >20% correlated for Grade ≥ II leucopenia and neutropenia. None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis. CONCLUSION: The IMRT arm of NCT01279135 (PARCER study) that employed strict bowel constraints had unintentional but desirable BM sparing. None of the BM subvolume DVH parameters could be validated on multivariate analysis. ADVANCES IN KNOWLEDGE: The prospective study reports feasibility of bone marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cervical cancer. The present study reports low incidence of hematological and gastrointestinal toxicity during post-operative chemoradiation with IMRT. As both whole bone and freehand pelvis BM contours predicted for HT, hence an easier method of whole bone contouring should continue to be used till further validation of more specific BM subvolumes becomes available. The study results highlight the need for further research into dose volume constraints during post-operative IMRT.
Authors: Loren K Mell; Joel D Kochanski; John C Roeske; Josh J Haslam; Neil Mehta; S Diane Yamada; Jean A Hurteau; Yvonne C Collins; Ernst Lengyel; Arno J Mundt Journal: Int J Radiat Oncol Biol Phys Date: 2006-06-06 Impact factor: 7.038
Authors: P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: P Mauch; L Constine; J Greenberger; W Knospe; J Sullivan; J L Liesveld; H J Deeg Journal: Int J Radiat Oncol Biol Phys Date: 1995-03-30 Impact factor: 7.038
Authors: C W Whitney; W Sause; B N Bundy; J H Malfetano; E V Hannigan; W C Fowler; D L Clarke-Pearson; S Y Liao Journal: J Clin Oncol Date: 1999-05 Impact factor: 44.544
Authors: Clark J Brixey; John C Roeske; Anthony E Lujan; S Diane Yamada; Jacob Rotmensch; Arno J Mundt Journal: Int J Radiat Oncol Biol Phys Date: 2002-12-01 Impact factor: 7.038
Authors: Loren K Mell; Igor Sirák; Lichun Wei; Rafal Tarnawski; Umesh Mahantshetty; Catheryn M Yashar; Michael T McHale; Ronghui Xu; Gordon Honerkamp-Smith; Ruben Carmona; Mary Wright; Casey W Williamson; Linda Kasaová; Nan Li; Stephen Kry; Jeff Michalski; Walter Bosch; William Straube; Julie Schwarz; Jessica Lowenstein; Steve B Jiang; Cheryl C Saenz; Steve Plaxe; John Einck; Chonlakiet Khorprasert; Paul Koonings; Terry Harrison; Mei Shi; A J Mundt Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-23 Impact factor: 7.038
Authors: W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell Journal: N Engl J Med Date: 1999-04-15 Impact factor: 91.245
Authors: Elizabeth K Nugent; Ashley S Case; John T Hoff; Israel Zighelboim; Lorri L DeWitt; Kim Trinkhaus; David G Mutch; Premal H Thaker; L Stewart Massad; Janet S Rader Journal: Gynecol Oncol Date: 2009-11-05 Impact factor: 5.482
Authors: Haixiao Wu; Shu Li; Yile Lin; Jun Wang; Vladimir P Chekhonin; Karl Peltzer; Vladimir P Baklaushev; Kirellos Said Abbas; Jin Zhang; Huiyang Li; Chao Zhang Journal: Front Nutr Date: 2022-07-28